Return to Calendar

Pacific Conversations with Professor Mamoun Alhamadsheh

Thursday, May 16, 2024
12:00 p.m. - 12:45 p.m.

Add to Calendar 2024-05-16 12:00:00 2024-05-16 12:45:00 Pacific Conversations with Professor Mamoun Alhamadsheh Vice President Scott Biedermann ’05, ’20 invites you to join him for a virtual conversation with Professor Mamoun Alhamadsheh.Dr. Mamoun Alhamadsheh is Professor of Pharmaceutical Chemistry at University of the Pacific and co-founder at Eidos Therapeutics. He is only the third Pacific professor in more than 20 years to receive an R01—the highest level of $1.7M competitive research grants from the National Institutes of Health to discover a better antidote for opioid overdoses. Most overdose deaths involve illicit synthetic opioids like fentanyl, the primary driver of the opioid epidemic today. The short duration of action (DOA) of opioid antagonists, naloxone and nalmefene, poses a significant challenge to their efficacy against fentanyl overdose, especially in mass casualty cases. Go into the lab with Dr. Alhamadsheh and his team as they work to develop a fundamentally novel drug delivery approach for extending the duration of action and efficacy of currently FDA-approved opioid overdose antidotes.The conversation will last approximately 45-minutes. Registration is required. Please use the link to register to receive the Zoom info to attend on May 16. We look forward to seeing you virtually!Thursday, May 1612 pm PTOnline via Zoom Alumni Association Thomas J. Long School of Pharmacy Alumni Association Thomas J. Long School of Pharmacy America/Los_Angeles public

Vice President Scott Biedermann ’05, ’20 invites you to join him for a virtual conversation with Professor Mamoun Alhamadsheh.

Dr. Mamoun Alhamadsheh is Professor of Pharmaceutical Chemistry at University of the Pacific and co-founder at Eidos Therapeutics. He is only the third Pacific professor in more than 20 years to receive an R01—the highest level of $1.7M competitive research grants from the National Institutes of Health to discover a better antidote for opioid overdoses.

Most overdose deaths involve illicit synthetic opioids like fentanyl, the primary driver of the opioid epidemic today. The short duration of action (DOA) of opioid antagonists, naloxone and nalmefene, poses a significant challenge to their efficacy against fentanyl overdose, especially in mass casualty cases. Go into the lab with Dr. Alhamadsheh and his team as they work to develop a fundamentally novel drug delivery approach for extending the duration of action and efficacy of currently FDA-approved opioid overdose antidotes.

The conversation will last approximately 45-minutes. Registration is required. Please use the link to register to receive the Zoom info to attend on May 16. We look forward to seeing you virtually!